根据Amphastar Pharmaceuticals向美国证券交易委员会（SEC）提交的文件显示，公司收到的一份美国食品药品监督管理局（FDA）警告信，并未要求其相关业务单元停止生产、限制销售或召回任何产品。
根据Amphastar Pharmaceuticals向美国证券交易委员会（SEC）提交的文件显示，公司收到的一份美国食品药品监督管理局（FDA）警告信，并未要求其相关业务单元停止生产、限制销售或召回任何产品。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.